In a double-blind randomized clinical trial for a new drug, both 'blinding' elements refer to:
- AThe drug is administered in two doses that neither patients nor doctors know about.
- BTwo separate clinical teams independently analyze the data without communicating.
- CThe patients are unaware of their treatment, and the researchers analyzing data are unaware of treatment assignments.Correct
- DThe control group receives no treatment, and both groups are unaware of their assignment.
Why C is right
In a double-blind trial, two groups are blinded: (1) Subjects/patients do not know whether they receive the treatment or placebo — preventing the placebo effect from biasing results. (2) Researchers and clinicians administering and evaluating treatments do not know which group received which treatment — preventing observer bias. Both forms of bias can distort outcomes in ways that favor the treatment, which is why double-blinding is considered the gold standard for clinical trials.
Why the other 3 choices miss
- A
- Incorrect. 'Double-blind' refers to who is blinded (subjects and researchers), not to the dose structure. Two doses are not part of the definition of a double-blind trial.
- B
- Incorrect. Independent analysis teams are part of some research integrity procedures but are not what 'double-blind' means. Double-blind refers to blinding of subjects and researchers/evaluators, not independent teams.
- D
- Incorrect. A control group receiving no treatment (or a placebo) is a feature of controlled trials in general, not specifically of double-blinding. Double-blinding specifically refers to who is unaware of treatment status.